Company: PMVP
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0000950170-25-104588
Chunk: 8

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Item 3
Chunk 8
---
We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks.

We had cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025. The Company’s cash equivalents consist of interest-bearing U.S. government securities, money market funds, and corporate debt securities. Our exposure due to changes in interest rates is not material due to the nature and amount of our money-market funds and marketable securities.

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we may contract with foreign vendors that are located outside the United States in the future. This may subject us to fluctuations in foreign currency exchange rates in the future.